2019 Future of Guillain-Barre Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 40 pages | ID: 2E612E9E6F7EN
VPAResearch

Abstracts

The global demand for Guillain-Barre Syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Guillain-Barre Syndrome pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Guillain-Barre Syndrome pipeline companies from advancing their products into Phase 3 or Phase 4.

Guillain-Barre Syndrome Report Description-

The 2019 pipeline study on Guillain-Barre Syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Guillain-Barre Syndrome pipeline compounds.

The Guillain-Barre Syndrome pipeline guide presents information on all active drugs currently being developed for Guillain-Barre Syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Guillain-Barre Syndrome pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Guillain-Barre Syndrome drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Guillain-Barre Syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Guillain-Barre Syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Guillain-Barre Syndrome pipeline report includes-

• An overview of Guillain-Barre Syndrome disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Guillain-Barre Syndrome pipeline
• Company wise list of Guillain-Barre Syndrome pipeline
• Mechanism of Action wise Guillain-Barre Syndrome pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Guillain-Barre Syndrome pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Guillain-Barre Syndrome pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Guillain-Barre Syndrome pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL GUILLAIN-BARRE SYNDROME PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Guillain-Barre Syndrome Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Guillain-Barre Syndrome pipeline, H1- 2019
3.5 Mechanism of Action wise Guillain-Barre Syndrome Pipeline Candidates

4 AKARI THERAPEUTICS PLC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

4.1 Akari Therapeutics Plc Business Profile
4.2 Akari Therapeutics Plc Guillain-Barre Syndrome Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 ALEXION PHARMACEUTICALS GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

5.1 Alexion Pharmaceuticals Business Profile
5.2 Alexion Pharmaceuticals Guillain-Barre Syndrome Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 ANNEXON INC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

6.1 Annexon Inc Business Profile
6.2 Annexon Inc Guillain-Barre Syndrome Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 CELLENKOS GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

7.1 Cellenkos Business Profile
7.2 Cellenkos Guillain-Barre Syndrome Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 COMPLEMENT PHARMA BV GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

8.1 Complement Pharma BV Business Profile
8.2 Complement Pharma BV Guillain-Barre Syndrome Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 CURAVAC INC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

9.1 CuraVac Inc Business Profile
9.2 CuraVac Inc Guillain-Barre Syndrome Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 HANSA MEDICAL AB GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

10.1 Hansa Medical AB Business Profile
10.2 Hansa Medical AB Guillain-Barre Syndrome Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 PRONOXIS GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

11.1 ProNoxis Business Profile
11.2 ProNoxis Guillain-Barre Syndrome Drug Details
11.3 Drug Snapshot
  11.3.1 Originator
  11.3.2 Collaborator/Co-Developer
  11.3.3 Route of Administration
  11.3.4 Orphan Drug/Fast Track/Special Designation
  11.3.5 Geography
  11.3.6 Type of Molecular Entity
  11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 VITALITY BIOPHARMA INC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

12.1 Vitality Biopharma Inc Business Profile
12.2 Vitality Biopharma Inc Guillain-Barre Syndrome Drug Details
12.3 Drug Snapshot
  12.3.1 Originator
  12.3.2 Collaborator/Co-Developer
  12.3.3 Route of Administration
  12.3.4 Orphan Drug/Fast Track/Special Designation
  12.3.5 Geography
  12.3.6 Type of Molecular Entity
  12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. LATEST GUILLAIN-BARRE SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019

14. APPENDIX

14.1 About Us
14.2 Sources and Methodology
14.3 Contact Information